Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index \>= 25 kg/m2~* Body Weight \> 50 kg~* Liver fat (assessed via MRI-PDFF) \>= 8%~* Biopsy-proven NASH - diagnosed in previous 24-months~* Presumed NASH - per Sponsor's definition~* NAFLD with minimal inflammation/fibrosis~* Features of Metabolic Syndrome~Exclusion Criteria:~* Alcohol-induced steatohepatitis or other forms of chronic liver disease~* Positive for Hepatitis B, Hepatitis C, or Human Deficiency Virus~* Severe Renal Impairment~* Contraindications for MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Double-Blind, PF-05221304-matching Placebo
- PF-05221304 - 2 mg (Type: ACTIVE_COMPARATOR): PF-05221304 - 2 mg, once-daily
- PF-05221304 - 10 mg (Type: ACTIVE_COMPARATOR): PF-05221304 - 10 mg, once-daily
- PF-05221304 - 25 mg (Type: ACTIVE_COMPARATOR): PF-05221304 - 25 mg, once-daily
- PF-05221304 - 50 mg (Type: ACTIVE_COMPARATOR): PF-05221304 - 50 mg, once-daily

Based on this trial design, predict the completion outcome and termination type (if applicable).